M. T. Oezbek

Long-term efficacy of the peptide-based COVID-19 T cell activator CoVac-1 in healthy adults

M. Schindler, K. Wiesmüller, M. Bitzer, 2023, medRxiv.

Phase I/II trial of a peptide-based COVID-19 T-cell activator in patients with B-cell deficiency

K. Wiesmüller, Melanie Märklin, A. Nelde, 2023, Nature communications.